These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 33906312)
1. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs. El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312 [TBL] [Abstract][Full Text] [Related]
2. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Sankar K; Stein BL; Rampal RK Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487 [TBL] [Abstract][Full Text] [Related]
3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633 [TBL] [Abstract][Full Text] [Related]
4. Thrombosis among 1537 patients with JAK2 Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Shallis RM; Zeidan AM; Wang R; Podoltsev NA Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862 [TBL] [Abstract][Full Text] [Related]
6. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Masarova L; Verstovsek S Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809 [TBL] [Abstract][Full Text] [Related]
7. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm. Chen P; Ouyang J; Liang J; Yu X; Huang B Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603 [TBL] [Abstract][Full Text] [Related]
8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
9. Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575 [TBL] [Abstract][Full Text] [Related]
10. Leukocytosis and MPNs: Where do we stand? Coltoff A Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233 [TBL] [Abstract][Full Text] [Related]
11. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms. Mora B; Passamonti F Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275 [TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542 [TBL] [Abstract][Full Text] [Related]
13. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656 [TBL] [Abstract][Full Text] [Related]
14. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Hasselbalch HC Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709 [TBL] [Abstract][Full Text] [Related]
15. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068 [TBL] [Abstract][Full Text] [Related]
16. CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms. Hodeib H; Abd El Hai D; Tawfik MA; Allam AA; Selim A; Elsawy AA; Youssef A Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328046 [TBL] [Abstract][Full Text] [Related]
17. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
18. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A; Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858 [TBL] [Abstract][Full Text] [Related]